NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
Deciphera Pharmaceuticals, LLC
Novartis
Novartis
Novartis
Turning Point Therapeutics, Inc.
Novartis
Novartis
GlaxoSmithKline
Sierra Oncology LLC - a GSK company
Clovis Oncology, Inc.
GlaxoSmithKline
Merrimack Pharmaceuticals
GlaxoSmithKline